25 XP   0   0   10

Purple Biotech
Buy, Hold or Sell?

Let's analyse Purple Biotech together

PenkeI guess you are interested in Purple Biotech. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Purple Biotech. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Purple Biotech

I send you an email if I find something interesting about Purple Biotech.

Quick analysis of Purple Biotech (30 sec.)










What can you expect buying and holding a share of Purple Biotech? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.29
Expected worth in 1 year
$0.81
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
$-0.48
Return On Investment
-94.0%

For what price can you sell your share?

Current Price per Share
$0.51
Expected price per share
$0.3023 - $0.6004
How sure are you?
50%

1. Valuation of Purple Biotech (5 min.)




Live pricePrice per Share (EOD)

$0.51

Intrinsic Value Per Share

$-12.98 - $-15.38

Total Value Per Share

$-11.69 - $-14.09

2. Growth of Purple Biotech (5 min.)




Is Purple Biotech growing?

Current yearPrevious yearGrowGrow %
How rich?$34.2m$53.2m-$12.5m-30.9%

How much money is Purple Biotech making?

Current yearPrevious yearGrowGrow %
Making money-$4.9m-$5.2m$249.5k5.0%
Net Profit Margin0.0%149.8%--

How much money comes from the company's main activities?

3. Financial Health of Purple Biotech (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#519 / 1010

Most Revenue
#739 / 1010

Most Profit
#424 / 1010

Most Efficient
#181 / 1010

What can you expect buying and holding a share of Purple Biotech? (5 min.)

Welcome investor! Purple Biotech's management wants to use your money to grow the business. In return you get a share of Purple Biotech.

What can you expect buying and holding a share of Purple Biotech?

First you should know what it really means to hold a share of Purple Biotech. And how you can make/lose money.

Speculation

The Price per Share of Purple Biotech is $0.5127. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Purple Biotech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Purple Biotech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.29. Based on the TTM, the Book Value Change Per Share is $-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Purple Biotech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.18-35.5%-0.15-28.7%-0.20-39.8%-0.19-36.4%-0.17-32.4%
Usd Book Value Change Per Share-0.17-32.5%-0.12-23.5%-0.17-33.1%0.0510.1%0.0612.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.17-32.5%-0.12-23.5%-0.17-33.1%0.0510.1%0.0612.0%
Usd Price Per Share0.78-1.29-2.43-2.42-2.22-
Price to Earnings Ratio-1.07--4.79--3.10--31.16--27.50-
Price-to-Total Gains Ratio-4.68--229.71--15.43--73.12--67.99-
Price to Book Ratio0.60-2.32-1.19-1.62-1.81-
Price-to-Total Gains Ratio-4.68--229.71--15.43--73.12--67.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.5127
Number of shares1950
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.120.05
Usd Total Gains Per Share-0.120.05
Gains per Quarter (1950 shares)-234.97101.44
Gains per Year (1950 shares)-939.89405.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-940-9500406396
20-1880-18900812802
30-2820-2830012171208
40-3760-3770016231614
50-4699-4710020292020
60-5639-5650024352426
70-6579-6590028402832
80-7519-7530032463238
90-8459-8470036523644
100-9399-9410040584050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%4.011.03.022.2%6.012.03.028.6%6.012.03.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%4.011.03.022.2%6.012.03.028.6%6.012.03.028.6%

Fundamentals of Purple Biotech

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Fundamental data was last updated by Penke on 2024-04-12 15:30:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Purple Biotech.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Purple Biotech earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Purple Biotech:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY149.8%-149.8%
TTM-5Y-34.3%+34.3%
5Y-34.3%10Y-29.4%-4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY149.8%-288.3%+438.1%
5Y-34.3%-449.1%+414.8%
10Y-29.4%-605.5%+576.1%
1.1.2. Return on Assets

Shows how efficient Purple Biotech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • -10.9% Return on Assets means that Purple Biotech generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Purple Biotech:

  • The MRQ is -10.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.9%TTM-10.5%-0.4%
TTM-10.5%YOY-8.6%-1.8%
TTM-10.5%5Y-11.8%+1.3%
5Y-11.8%10Y-16.7%+4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.9%-13.3%+2.4%
TTM-10.5%-12.8%+2.3%
YOY-8.6%-11.7%+3.1%
5Y-11.8%-13.9%+2.1%
10Y-16.7%-15.7%-1.0%
1.1.3. Return on Equity

Shows how efficient Purple Biotech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • -14.1% Return on Equity means Purple Biotech generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Purple Biotech:

  • The MRQ is -14.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.1%TTM-12.4%-1.7%
TTM-12.4%YOY-9.9%-2.6%
TTM-12.4%5Y-15.2%+2.8%
5Y-15.2%10Y-64.3%+49.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.1%-16.9%+2.8%
TTM-12.4%-16.1%+3.7%
YOY-9.9%-15.1%+5.2%
5Y-15.2%-19.3%+4.1%
10Y-64.3%-20.2%-44.1%

1.2. Operating Efficiency of Purple Biotech.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Purple Biotech is operating .

  • Measures how much profit Purple Biotech makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Purple Biotech:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY181.3%-181.3%
TTM-5Y-35.9%+35.9%
5Y-35.9%10Y-30.8%-5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY181.3%-298.2%+479.5%
5Y-35.9%-492.1%+456.2%
10Y-30.8%-632.4%+601.6%
1.2.2. Operating Ratio

Measures how efficient Purple Biotech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Purple Biotech:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-1.827+1.827
TTM-5Y0.817-0.817
5Y0.81710Y0.700+0.117
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-1.8273.890-5.717
5Y0.8175.739-4.922
10Y0.7007.876-7.176

1.3. Liquidity of Purple Biotech.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Purple Biotech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.20 means the company has $2.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Purple Biotech:

  • The MRQ is 2.198. The company is able to pay all its short-term debts. +1
  • The TTM is 3.302. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.198TTM3.302-1.104
TTM3.302YOY5.816-2.515
TTM3.3025Y7.387-4.085
5Y7.38710Y6.901+0.485
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1983.890-1.692
TTM3.3024.173-0.871
YOY5.8165.344+0.472
5Y7.3876.126+1.261
10Y6.9016.448+0.453
1.3.2. Quick Ratio

Measures if Purple Biotech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • A Quick Ratio of 2.27 means the company can pay off $2.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Purple Biotech:

  • The MRQ is 2.274. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.400. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.274TTM2.400-0.126
TTM2.400YOY8.686-6.286
TTM2.4005Y9.435-7.035
5Y9.43510Y8.650+0.784
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2743.514-1.240
TTM2.4003.998-1.598
YOY8.6865.380+3.306
5Y9.4356.105+3.330
10Y8.6506.404+2.246

1.4. Solvency of Purple Biotech.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Purple Biotech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Purple Biotech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Purple Biotech assets are financed with 22.6% credit (debt) and the remaining percentage (100% - 22.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Purple Biotech:

  • The MRQ is 0.226. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.148. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.148+0.077
TTM0.148YOY0.117+0.032
TTM0.1485Y0.151-0.003
5Y0.15110Y0.206-0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2260.339-0.113
TTM0.1480.336-0.188
YOY0.1170.271-0.154
5Y0.1510.366-0.215
10Y0.2060.389-0.183
1.4.2. Debt to Equity Ratio

Measures if Purple Biotech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Purple Biotech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.2% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Purple Biotech:

  • The MRQ is 0.292. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.179. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.292TTM0.179+0.114
TTM0.179YOY0.133+0.046
TTM0.1795Y0.197-0.018
5Y0.19710Y0.748-0.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2920.388-0.096
TTM0.1790.402-0.223
YOY0.1330.335-0.202
5Y0.1970.426-0.229
10Y0.7480.461+0.287

2. Market Valuation of Purple Biotech

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Purple Biotech generates.

  • Above 15 is considered overpriced but always compare Purple Biotech to the Biotechnology industry mean.
  • A PE ratio of -1.07 means the investor is paying $-1.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Purple Biotech:

  • The EOD is -0.705. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.073. Based on the earnings, the company is expensive. -2
  • The TTM is -4.791. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.705MRQ-1.073+0.368
MRQ-1.073TTM-4.791+3.719
TTM-4.791YOY-3.096-1.696
TTM-4.7915Y-31.158+26.367
5Y-31.15810Y-27.495-3.663
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.705-2.264+1.559
MRQ-1.073-2.629+1.556
TTM-4.791-2.680-2.111
YOY-3.096-4.145+1.049
5Y-31.158-6.257-24.901
10Y-27.495-6.254-21.241
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Purple Biotech:

  • The EOD is -0.692. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.053. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.788. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.692MRQ-1.053+0.361
MRQ-1.053TTM-4.788+3.734
TTM-4.788YOY-3.748-1.040
TTM-4.7885Y-22.635+17.847
5Y-22.63510Y-20.474-2.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.692-2.973+2.281
MRQ-1.053-3.333+2.280
TTM-4.788-3.553-1.235
YOY-3.748-5.605+1.857
5Y-22.635-8.376-14.259
10Y-20.474-8.865-11.609
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Purple Biotech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.60 means the investor is paying $0.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Purple Biotech:

  • The EOD is 0.397. Based on the equity, the company is cheap. +2
  • The MRQ is 0.604. Based on the equity, the company is cheap. +2
  • The TTM is 2.316. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.397MRQ0.604-0.207
MRQ0.604TTM2.316-1.712
TTM2.316YOY1.186+1.130
TTM2.3165Y1.622+0.694
5Y1.62210Y1.813-0.191
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3971.896-1.499
MRQ0.6042.115-1.511
TTM2.3162.093+0.223
YOY1.1862.884-1.698
5Y1.6223.542-1.920
10Y1.8133.916-2.103
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Purple Biotech.

3.1. Institutions holding Purple Biotech

Institutions are holding 9.162% of the shares of Purple Biotech.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Armistice Capital, LLC7.25590.02188217318821730
2023-12-31Wuxi AppTec Co Ltd0.74840.39261941391941390
2023-12-31Kingswood Wealth Advisors LLC0.6750.01551751004445034.0222
2023-12-31Morgan Stanley - Brokerage Accounts0.333508651356113184.5822
2023-12-31Venture Visionary Partners LLC0.060.0006155539916.8054
2023-12-31Wealth Advisors OF Iowa, LLC0.0550.00751427010007.5358
2023-09-30Citadel Advisors Llc0.0537013925-32019-69.6914
2023-12-31XTX Topco Ltd0.05230.002313561135610
2023-12-31Geode Capital Management, LLC0.048801266600
2023-12-31Raymond James & Associates0.042401100000
2023-12-31TD Waterhouse Canada Inc0.01540400000
2023-12-31SIMPLEX TRADING, LLC0.014903874-3899-50.1608
2023-12-31Group One Trading, LP0.0130338200
2023-12-31UBS Group AG0.0077020001337.1237
2023-12-31Advisory Services Network, LLC0.00770199519950
2023-12-31Rhumbline Advisers0.0021055500
2023-12-31Global Retirement Partners, LLC.0.0013033600
2023-12-31North Star Investment Management Corp0.0012030000
2023-12-31Sound Income Strategies0.000401001000
2023-12-31Royal Bank of Canada008-100-92.5926
Total 9.38870.43852435450+2158637+88.6%

3.2. Funds holding Purple Biotech

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.04870.00011266600
Total 0.04870.00011266600.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Purple Biotech compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.167-0.120-28%-0.170+2%0.052-420%0.061-371%
Book Value Per Share--1.2911.181+9%2.007-36%1.765-27%1.531-16%
Current Ratio--2.1983.302-33%5.816-62%7.387-70%6.901-68%
Debt To Asset Ratio--0.2260.148+52%0.117+94%0.151+49%0.206+10%
Debt To Equity Ratio--0.2920.179+64%0.133+120%0.197+49%0.748-61%
Dividend Per Share----0%-0%-0%-0%
Eps---0.182-0.147-19%-0.204+12%-0.187+3%-0.166-9%
Free Cash Flow Per Share---0.185-0.144-22%-0.160-14%-0.125-33%-0.112-39%
Free Cash Flow To Equity Per Share---0.025-0.096+287%-0.149+504%0.035-171%0.044-156%
Gross Profit Margin--1.0001.0000%1.0000%0.889+13%0.905+11%
Intrinsic Value_10Y_max---15.378--------
Intrinsic Value_10Y_min---12.981--------
Intrinsic Value_1Y_max---0.735--------
Intrinsic Value_1Y_min---0.722--------
Intrinsic Value_3Y_max---2.823--------
Intrinsic Value_3Y_min---2.683--------
Intrinsic Value_5Y_max---5.652--------
Intrinsic Value_5Y_min---5.193--------
Market Cap13616542.950-52%20715630.00097979187.816-79%64603551.250-68%78363414.459-74%71152415.965-71%
Net Profit Margin----0%1.498-100%-0.3430%-0.2940%
Operating Margin----0%1.813-100%-0.3590%-0.3080%
Operating Ratio----0%-1.8270%0.817-100%0.700-100%
Pb Ratio0.397-52%0.6042.316-74%1.186-49%1.622-63%1.813-67%
Pe Ratio-0.705+34%-1.073-4.791+347%-3.096+189%-31.158+2805%-27.495+2463%
Price Per Share0.513-52%0.7801.289-39%2.433-68%2.417-68%2.222-65%
Price To Free Cash Flow Ratio-0.692+34%-1.053-4.788+354%-3.748+256%-22.635+2049%-20.474+1843%
Price To Total Gains Ratio-3.079+34%-4.685-229.713+4803%-15.432+229%-73.120+1461%-67.988+1351%
Quick Ratio--2.2742.400-5%8.686-74%9.435-76%8.650-74%
Return On Assets---0.109-0.105-4%-0.086-21%-0.118+8%-0.167+53%
Return On Equity---0.141-0.124-12%-0.099-30%-0.152+8%-0.643+355%
Total Gains Per Share---0.167-0.120-28%-0.170+2%0.052-420%0.061-371%
Usd Book Value--34297000.00040701750.000-16%53295500.000-36%48937777.778-30%42438714.286-19%
Usd Book Value Change Per Share---0.167-0.120-28%-0.170+2%0.052-420%0.061-371%
Usd Book Value Per Share--1.2911.181+9%2.007-36%1.765-27%1.531-16%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.182-0.147-19%-0.204+12%-0.187+3%-0.166-9%
Usd Free Cash Flow---4915999.000-4965499.750+1%-4240750.000-14%-3565583.278-27%-3199214.238-35%
Usd Free Cash Flow Per Share---0.185-0.144-22%-0.160-14%-0.125-33%-0.112-39%
Usd Free Cash Flow To Equity Per Share---0.025-0.096+287%-0.149+504%0.035-171%0.044-156%
Usd Market Cap13616542.950-52%20715630.00097979187.816-79%64603551.250-68%78363414.459-74%71152415.965-71%
Usd Price Per Share0.513-52%0.7801.289-39%2.433-68%2.417-68%2.222-65%
Usd Profit---4828000.000-4970000.000+3%-5219500.000+8%-4841555.556+0%-4307952.381-11%
Usd Revenue----0%-227500.0000%42777.778-100%36666.667-100%
Usd Total Gains Per Share---0.167-0.120-28%-0.170+2%0.052-420%0.061-371%
 EOD+3 -5MRQTTM+9 -20YOY+12 -195Y+10 -2210Y+8 -24

4.2. Fundamental Score

Let's check the fundamental score of Purple Biotech based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.705
Price to Book Ratio (EOD)Between0-10.397
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.274
Current Ratio (MRQ)Greater than12.198
Debt to Asset Ratio (MRQ)Less than10.226
Debt to Equity Ratio (MRQ)Less than10.292
Return on Equity (MRQ)Greater than0.15-0.141
Return on Assets (MRQ)Greater than0.05-0.109
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Purple Biotech based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.476
Ma 20Greater thanMa 500.595
Ma 50Greater thanMa 1000.680
Ma 100Greater thanMa 2000.741
OpenGreater thanClose0.487
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets44,302
Total Liabilities10,005
Total Stockholder Equity34,207
 As reported
Total Liabilities 10,005
Total Stockholder Equity+ 34,207
Total Assets = 44,302

Assets

Total Assets44,302
Total Current Assets15,788
Long-term Assets28,514
Total Current Assets
Cash And Cash Equivalents 14,489
Short-term Investments 923
Other Current Assets 376
Total Current Assets  (as reported)15,788
Total Current Assets  (calculated)15,788
+/-0
Long-term Assets
Property Plant Equipment 470
Long-term Assets  (as reported)28,514
Long-term Assets  (calculated)470
+/- 28,044

Liabilities & Shareholders' Equity

Total Current Liabilities7,183
Long-term Liabilities2,822
Total Stockholder Equity34,207
Total Current Liabilities
Short-term Debt 188
Accounts payable 3,532
Other Current Liabilities 3,463
Total Current Liabilities  (as reported)7,183
Total Current Liabilities  (calculated)7,183
+/-0
Long-term Liabilities
Capital Lease Obligations 351
Long-term Liabilities  (as reported)2,822
Long-term Liabilities  (calculated)351
+/- 2,471
Total Stockholder Equity
Retained Earnings -137,453
Accumulated Other Comprehensive Income 38,476
Other Stockholders Equity 133,184
Total Stockholder Equity (as reported)34,207
Total Stockholder Equity (calculated)34,207
+/-0
Other
Cash and Short Term Investments 15,412
Common Stock Shares Outstanding 24,619
Liabilities and Stockholders Equity 44,302
Net Debt -14,138
Net Invested Capital 34,207
Net Working Capital 8,605
Property Plant and Equipment Gross 470
Short Long Term Debt Total 351



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-312018-06-302017-12-312017-06-302017-03-312016-12-312016-06-302015-12-312015-09-302015-06-302014-12-312014-09-30
> Total Assets 
0
1,759
2,009
1,540
10,812
9,088
14,914
14,914
15,086
14,183
18,376
14,723
17,191
0
14,718
0
85,783
0
83,803
81,954
76,491
73,628
70,198
66,294
61,740
58,543
54,622
53,082
47,999
45,272
44,302
44,30245,27247,99953,08254,62258,54361,74066,29470,19873,62876,49181,95483,803085,783014,718017,19114,72318,37614,18315,08614,91414,9149,08810,8121,5402,0091,7590
   > Total Current Assets 
0
1,759
2,003
1,534
10,804
9,077
14,898
14,898
8,894
7,983
12,174
8,514
10,668
8,302
8,302
65,160
65,160
59,282
59,282
57,442
50,001
47,197
48,473
41,899
37,447
34,306
33,256
24,410
19,384
16,718
15,788
15,78816,71819,38424,41033,25634,30637,44741,89948,47347,19750,00157,44259,28259,28265,16065,1608,3028,30210,6688,51412,1747,9838,89414,89814,8989,07710,8041,5342,0031,7590
       Cash And Cash Equivalents 
0
1,313
1,652
981
10,558
3,933
6,758
6,758
527
3,947
5,363
5,163
2,757
0
4,385
0
62,995
0
11,247
10,195
10,540
9,117
10,890
23,537
14,006
11,074
15,030
21,883
17,202
15,104
14,489
14,48915,10417,20221,88315,03011,07414,00623,53710,8909,11710,54010,19511,247062,99504,38502,7575,1635,3633,9475276,7586,7583,93310,5589811,6521,3130
       Short-term Investments 
0
0
0
0
0
4,500
7,899
7,899
7,605
0
6,467
1,521
7,060
0
2,010
0
10
0
46,558
45,258
37,846
36,447
36,310
16,010
22,010
22,010
17,083
1,235
1,198
980
923
9239801,1981,23517,08322,01022,01016,01036,31036,44737,84645,25846,55801002,01007,0601,5216,46707,6057,8997,8994,50000000
       Net Receivables 
0
420
351
553
124
644
151
151
762
0
0
743
0
3,493
1,493
1,000
1,000
500
500
500
500
500
0
0
0
0
0
0
0
0
0
0000000005005005005005001,0001,0001,4933,4930743007621511516441245533514200
       Other Current Assets 
0
26
0
0
122
4,500
7,899
7,899
7,605
171
344
81
851
182
1,907
1,155
1,155
197
977
1,489
1,115
1,133
1,273
2,352
1,431
1,222
1,143
1,292
984
634
376
3766349841,2921,1431,2221,4312,3521,2731,1331,1151,4899771971,1551,1551,907182851813441717,6057,8997,8994,50012200260
   > Long-term Assets 
0
0
6
6
8
11
16
16
6,192
6,200
6,202
6,209
6,523
0
6,416
0
20,623
0
24,521
24,512
26,490
26,431
21,725
24,395
24,293
24,237
21,366
28,672
28,615
28,554
28,514
28,51428,55428,61528,67221,36624,23724,29324,39521,72526,43126,49024,51224,521020,62306,41606,5236,2096,2026,2006,19216161186600
       Property Plant Equipment 
0
0
6
6
8
11
16
16
20
28
30
37
351
244
244
141
141
968
968
959
991
931
896
867
780
725
682
628
571
510
470
4705105716286827257808678969319919599689681411412442443513730282016161186600
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,663
20,663
0
28,016
0
0
0
00028,016020,66320,663000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
187
187
187
187
0
0
0
0
0
000001871871871870000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
6,172
6,172
0
6,172
6,172
0
6,172
0
0
0
20,482
0
0
0
20,482
0
21
21
20,684
28
0
0
0
0002820,6842121020,48200020,4820006,17206,1726,17206,1726,17200000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,071
3,071
3,071
5,017
5,018
160
2,657
2,642
2,641
0
0
0
0
0
000002,6412,6422,6571605,0185,0173,0713,0713,07100000000000000000
> Total Liabilities 
0
986
877
1,409
1,383
2,016
1,529
1,529
2,615
5,590
7,714
3,719
5,753
0
3,857
0
29,638
0
4,051
6,860
4,367
4,254
5,092
7,975
6,085
6,433
7,524
6,036
5,254
6,553
10,005
10,0056,5535,2546,0367,5246,4336,0857,9755,0924,2544,3676,8604,051029,63803,85705,7533,7197,7145,5902,6151,5291,5292,0161,3831,4098779860
   > Total Current Liabilities 
0
986
787
1,318
1,198
1,830
1,273
1,273
1,175
4,068
7,244
3,314
5,365
3,546
3,544
29,384
29,384
3,098
3,098
5,973
3,497
3,426
4,250
7,188
5,394
5,933
7,058
5,617
4,876
6,220
7,183
7,1836,2204,8765,6177,0585,9335,3947,1884,2503,4263,4975,9733,0983,09829,38429,3843,5443,5465,3653,3147,2444,0681,1751,2731,2731,8301,1981,3187879860
       Short-term Debt 
0
0
0
0
0
0
0
0
0
1,746
0
0
194
0
195
0
109
0
207
207
199
199
199
199
195
193
194
189
0
178
188
1881780189194193195199199199199207207010901950194001,746000000000
       Accounts payable 
0
500
228
321
353
1,045
515
515
370
215
767
705
861
1,245
1,243
2,965
2,965
1,198
1,198
1,335
2,071
2,083
1,473
1,651
1,227
2,765
2,132
2,451
1,572
2,593
3,532
3,5322,5931,5722,4512,1322,7651,2271,6511,4732,0832,0711,3351,1981,1982,9652,9651,2431,2458617057672153705155151,0453533212285000
       Other Current Liabilities 
0
486
559
997
845
785
758
758
805
2,012
6,477
2,609
2,451
961
1,145
26,310
24,403
1,693
1,693
4,431
1,227
1,144
2,578
5,338
3,972
2,975
4,732
2,977
3,120
3,449
3,463
3,4633,4493,1202,9774,7322,9753,9725,3382,5781,1441,2274,4311,6931,69324,40326,3101,1459612,4512,6096,4772,0128057587587858459975594860
   > Long-term Liabilities 
0
500
90
91
185
186
256
256
1,440
1,522
470
405
388
0
313
0
254
0
953
887
870
828
842
787
691
500
466
419
378
333
2,822
2,8223333784194665006917878428288708879530254031303884054701,5221,44025625618618591905000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
285
285
246
246
265
265
265
265
265
292
292
292
143
145
0
141
0
0
0014101451432922922922652652652652652462462852850000000000000
> Total Stockholder Equity
0
773
1,132
131
9,429
7,072
13,385
13,385
10,644
7,313
10,142
10,523
10,988
0
10,423
0
55,744
0
79,389
74,753
71,799
69,061
64,827
58,060
55,411
51,891
46,911
46,884
42,605
38,598
34,207
34,20738,59842,60546,88446,91151,89155,41158,06064,82769,06171,79974,75379,389055,744010,423010,98810,52310,1427,31310,64413,38513,3857,0729,4291311,1327730
   Common Stock0000000000000000000000000000000
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
1,321
1,040
1,294
1,297
1,085
1,344
1,344
2,627
2,486
1,615
1,616
2,350
0
3,084
0
6,599
0
8,017
8,727
9,266
9,666
8,764
8,889
9,181
9,688
10,060
10,597
0
10,184
38,476
38,47610,184010,59710,0609,6889,1818,8898,7649,6669,2668,7278,01706,59903,08402,3501,6161,6152,4862,6271,3441,3441,0851,2971,2941,0401,3210
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
9,304
11,626
11,627
22,186
23,078
38,241
38,241
40,041
43,394
51,852
52,579
54,885
12,957
56,860
29,600
126,446
38,001
148,893
150,094
150,229
150,229
151,968
152,373
152,968
153,765
154,426
158,738
37,949
161,041
133,184
133,184161,04137,949158,738154,426153,765152,968152,373151,968150,229150,229150,094148,89338,001126,44629,60056,86012,95754,88552,57951,85243,39440,04138,24138,24123,07822,18611,62711,6269,3040



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-199
Gross Profit-199-199
 
Operating Income (+$)
Gross Profit-199
Operating Expense-22,072
Operating Income-22,271-22,271
 
Operating Expense (+$)
Research Development17,034
Selling General Administrative4,842
Selling And Marketing Expenses0
Operating Expense22,07221,876
 
Net Interest Income (+$)
Interest Income474
Interest Expense-2,182
Other Finance Cost-1
Net Interest Income-1,707
 
Pretax Income (+$)
Operating Income-22,271
Net Interest Income-1,707
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-19,977-24,565
EBIT - interestExpense = -24,453
-19,977
-17,698
Interest Expense2,182
Earnings Before Interest and Taxes (EBIT)-22,271-17,795
Earnings Before Interest and Taxes (EBITDA)-22,072
 
After tax Income (+$)
Income Before Tax-19,977
Tax Provision-0
Net Income From Continuing Ops-19,977-19,977
Net Income-19,880
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses22,271
Total Other Income/Expenses Net2,2941,707
 

Technical Analysis of Purple Biotech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Purple Biotech. The general trend of Purple Biotech is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Purple Biotech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Purple Biotech.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.533 < 0.57 < 0.6004.

The bearish price targets are: 0.3023.

Tweet this
Purple Biotech Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Purple Biotech. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Purple Biotech Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Purple Biotech. The current macd is -0.06382468.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Purple Biotech price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Purple Biotech. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Purple Biotech price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Purple Biotech Daily Moving Average Convergence/Divergence (MACD) ChartPurple Biotech Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Purple Biotech. The current adx is 30.13.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Purple Biotech shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Purple Biotech Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Purple Biotech. The current sar is 0.60913021.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Purple Biotech Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Purple Biotech. The current rsi is 39.48. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Purple Biotech Daily Relative Strength Index (RSI) ChartPurple Biotech Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Purple Biotech. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Purple Biotech price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Purple Biotech Daily Stochastic Oscillator ChartPurple Biotech Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Purple Biotech. The current cci is -56.4585439.

Purple Biotech Daily Commodity Channel Index (CCI) ChartPurple Biotech Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Purple Biotech. The current cmo is -17.68575304.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Purple Biotech Daily Chande Momentum Oscillator (CMO) ChartPurple Biotech Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Purple Biotech. The current willr is -54.24097434.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Purple Biotech is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Purple Biotech Daily Williams %R ChartPurple Biotech Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Purple Biotech.

Purple Biotech Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Purple Biotech. The current atr is 0.08464406.

Purple Biotech Daily Average True Range (ATR) ChartPurple Biotech Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Purple Biotech. The current obv is -8,334,432.

Purple Biotech Daily On-Balance Volume (OBV) ChartPurple Biotech Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Purple Biotech. The current mfi is 34.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Purple Biotech Daily Money Flow Index (MFI) ChartPurple Biotech Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Purple Biotech.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Purple Biotech Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Purple Biotech based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.476
Ma 20Greater thanMa 500.595
Ma 50Greater thanMa 1000.680
Ma 100Greater thanMa 2000.741
OpenGreater thanClose0.487
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Purple Biotech with someone you think should read this too:
  • Are you bullish or bearish on Purple Biotech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Purple Biotech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Purple Biotech

I send you an email if I find something interesting about Purple Biotech.


Comments

How you think about this?

Leave a comment

Stay informed about Purple Biotech.

Receive notifications about Purple Biotech in your mailbox!